CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 18 enrolled
Drug / intervention
Rituximab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00695097
NCT00695097N/ACompleted
CompareCT.gov

The Effect of Rituximab on the Development of Anti-Donor Antibodies and Resolution of B Cell Infiltration in the Renal Allograft of Patients Undergoing Rejection

University of California, San Francisco·interventional·Posted Jun 11, 2008·Updated Mar 26, 2014

In Brief

A clinical study evaluating Rituximab and No Rituximab for Renal Transplant Rejection. Completed, enrolled 18 participants across 2 sites.

Detailed Summary

The aim of the study is to find out if Rituximab, which is an antibody against specific white cells involved in rejection, when combined with standard anti-rejection treatment can more effectively reverse the rejection process. Our hypothesis is that with acute rejection there is activation of B cells and the subsequent development of anti-donor antibodies that ultimately lead to graft loss. More effective therapy targeted at B cells may abort the development of anti-HLA antibodies, prevent renal injury and have a favorable effect on long-term graft outcome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Transplant Rejection
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 11, 2008
Enrollment StartAug 1, 2004
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 18.1 years ago

Interventions

Rituximabdrug

Rituximab infusion on Day 1 and Day 15

No Rituximabdrug

No Rituximab